Hypoparathyroidism secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(7 intermediate revisions by one other user not shown)
Line 2: Line 2:
{{Hypoparathyroidism}}
{{Hypoparathyroidism}}


{{CMG}}; {{AE}} {{DAMI}}
{{CMG}}; {{AE}} {{Anmol}}


==Overview==
==Overview==
There are no established measures for the secondary prevention of [disease name].
Effective measures for the secondary prevention of hypoparathyroidism is monitoring of patients on [[Hypoparathyroidism medical therapy|conventional therapy]]. Monitoring guidelines on conventional therapy include measurement of serum [[calcium]] ([[Hypoparathyroidism laboratory findings|corrected for albumin]]), [[phosphorus]], and [[creatinine]] concentrations;  24 hour [[urinary]] [[calcium]] [[excretion]] and  creatinine, and other imaging studies and examinations.
 
OR
 
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].


==Secondary Prevention==
==Secondary Prevention==
*There are no established measures for the secondary prevention of [disease name].
*Effective measures for the secondary prevention of hypoparathyroidism is monitoring of patients on [[Hypoparathyroidism medical therapy|conventional therapy]]. Monitoring guidelines on conventional therapy include:<ref name="pmid26943719">{{cite journal |vauthors=Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT |title=Management of Hypoparathyroidism: Summary Statement and Guidelines |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2273–83 |year=2016 |pmid=26943719 |doi=10.1210/jc.2015-3907 |url=}}</ref><ref name="pmid26938200">{{cite journal |vauthors=Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT |title=Management of Hypoparathyroidism: Present and Future |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2313–24 |year=2016 |pmid=26938200 |pmc=5393596 |doi=10.1210/jc.2015-3910 |url=}}</ref>
OR
**Serum [[calcium]] ([[Hypoparathyroidism laboratory findings|corrected for albumin]]), [[phosphorus]], and [[creatinine]] concentrations should be measured weekly to monthly during dose adjustments, and twice annually once a stable regimen has been reached.
*Effective measures for the secondary prevention of [disease name] include:
**24 Hour [[urinary]] [[calcium]] [[excretion]] and  creatinine should be considered during dose adjustments and should be measured twice annually on a stable regimen to evaluate for [[renal]] toxicity.
**[Strategy 1]
**Estimated [[glomerular filtration rate]] (e[[GFR]]) should be monitored yearly or more frequently if the clinical situation is appropriate.
**[Strategy 2]
*Other imaging studies and examinations may be done as clinically indicated including:
**[Strategy 3]
**[[Renal]] [[imaging]] may be done to rule out [[nephrolithiasis]]/[[nephrocalcinosis]].
**[[Ophthalmological]] exam may be done to rule out [[cataracts]].
**[[Central nervous system]] [[imaging]] may be done to rule out [[Basal ganglia calcification|basal ganglia]] and other sites of [[calcification]].
**[[Bone mineral density]] (BMD) by [[Dual energy X-ray absorptiometry]] ([[DXA]]) may be done to rule out to rule out [[Skeleton|skeletal]] abnormalities.


==References==
==References==
Line 24: Line 23:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Parathyroid disorders]]
[[Category:Up-To-Date]]

Latest revision as of 22:19, 29 July 2020

Hypoparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoparathyroidism secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoparathyroidism secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoparathyroidism secondary prevention

CDC on Hypoparathyroidism secondary prevention

Hypoparathyroidism secondary prevention in the news

Blogs on Hypoparathyroidism secondary prevention

Directions to Hospitals Treating Hypoparathyroidism

Risk calculators and risk factors for Hypoparathyroidism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Overview

Effective measures for the secondary prevention of hypoparathyroidism is monitoring of patients on conventional therapy. Monitoring guidelines on conventional therapy include measurement of serum calcium (corrected for albumin), phosphorus, and creatinine concentrations; 24 hour urinary calcium excretion and creatinine, and other imaging studies and examinations.

Secondary Prevention

References

  1. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT (2016). "Management of Hypoparathyroidism: Summary Statement and Guidelines". J. Clin. Endocrinol. Metab. 101 (6): 2273–83. doi:10.1210/jc.2015-3907. PMID 26943719.
  2. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future". J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.

Template:WH Template:WS